George Blanck, PhD

Associations

• Immuno-Oncology Program

Education & Training

Graduate:

• Columbia University, PhD - Cell and Molecular Biology

Fellowship:

• Universite de Paris VI - INSERM
• Harvard University, Cambridge, Massachusetts - Multiple Sclerosis
• Columbia University, New York, NY - Biological Sciences

• Charkowick SV, Huda TI, Patel DN, Yeagley M, Arturo JF, Cios KJ, Gozlan EC, Chobrutskiy A, Chobrutskiy BI, Blanck G. IGL CDR3 Hydropathy and Antigen Chemical Complementarity Associated with Greater Disease-Free Survival in Lung Adenocarcinoma: Implications for Gender Disparities. Biochem Genet. 2024 Feb.62(1):530-546. Pubmedid: 37392243.
• Angelakakis G, Varkhedi M, Dabkowski TR, Diaz MJ, Yeagley M, Blanck G. B-cell ALL with SOX11 gene amplification associates with a worse outcome. Cell Cycle. 2024 Feb.1-7. Pubmedid: 38350028.
• Alkassab L, Diaz MJ, Fetcher EA, Huda TI, Paul S, Kumar S, Chobrutskiy A, Chobrutskiy BI, Song JJ, Blanck G. TCR CDR3-CMV Antigen Chemical Complementaries Are Associated With a Worse Outcome for Renal Cell Carcinoma. Anticancer Res. 2024 Apr.44(4):1505-1511. Pubmedid: 38537966.
• Quach JU, Diaz MJ, Huda TI, Kinskey JC, Zaman S, Desantis JE, Cios KJ, Blanck G. Bacterial Sequencing Reads in Blood Exome Files from Melanoma and Cervical Cancer Patients are Associated with Cancer Recurrence. Mol Biotechnol. 2023 Sep.65(9):1476-1484. Pubmedid: 36653589.
• Kacsoh DB, Diaz MJ, Gozlan EC, Sahoo A, Song JJ, Yeagley M, Chobrutskiy A, Chobrutskiy BI, Blanck G. Blood-based T cell receptor anti-viral CDR3s are associated with worse overall survival for neuroblastoma. J Cancer Res Clin Oncol. 2023 Oct.149(13):12047-12056. Pubmedid: 37421457.
• Cheng P, Cios KJ, Varkhedi M, Barker VR, Yeagley M, Chobrutskiy A, Chobrutskiy BI, Blanck G. An immunoinformatics assessment of the cancer testis antigen, DDX53, as a potential early esophageal cancer antigen. Oncoscience. 2023 Nov.10:59-66. Pubmedid: 37953875. Pmcid: PMC10637345.
• Mwangi KW, Kamita MK, Waweru JW, Sayed S, Figueroa JD, Ambs S, Cios KJ, Blanck G, Makokha FW. Adaptive immune receptor features related to breast cancer tissue in Kenyan patients: high immunoglobulin gene expression and high levels of gamma-delta T-cells. Breast Cancer Res Treat. 2023 May.199(1):207-214. Pubmedid: 36882607.
• Mandala SR, Thomson AJ, Gozlan EC, Patel DN, Chobrutskiy A, Chobrutskiy BI, Blanck G. A Bioinformatics Assessment Indicating Better Outcomes With Breast Cancer Resident, Immunoglobulin CDR3-MMP2 Binding. Cancer Genomics Proteomics. 2023 May.20(3):239-246. Pubmedid: 37093687. Pmcid: PMC10148069.
• Pakasticali N, Chobrutskiy A, Patel DN, Hsiang M, Zaman S, Cios KJ, Blanck G, Chobrutskiy BI. Chemical Complementarity of Breast Cancer Resident, T-Cell Receptor CDR3 Domains and the Cancer Antigen, ARMC3, is Associated With Higher Levels of Survival and Granzyme Expression. Cancer Inform. 2023 Jun.22. Pubmedid: 37313373. Pmcid: PMC10259117.
• Hudock TR, Barker VR, Manley BJ, Chobrutskiy A, Chobrutskiy BI, Diaz MJ, Song JJ, Blanck G. TRB CDR3-cancer testis antigen chemical complementarity scoring for identifying productive immune responses in renal cell carcinoma. Cancer Biomark. 2023 Jul. Pubmedid: 37545223.
• Patel AR, Patel DN, Tu YN, Yeagley M, Chobrutskiy A, Chobrutskiy BI, Blanck G. Chemical complementarity between immune receptor CDR3s and candidate cancer antigens correlating with reduced survival: evidence for outcome mitigation with corticosteroid treatments. J Biomol Struct Dyn. 2023 Jul.41(10):4632-4640. Pubmedid: 35538689.
• Waweru JW, Mwangi KW, Barker VR, Gozlan EC, Yeagley M, Blanck G, Makokha FW. Delineation of a T-cell receptor CDR3-cancer mutanome aromaticity factor, assessable via blood samples, that facilitates the establishment of survival distinctions in bladder cancer. J Cancer Res Clin Oncol. 2023 Jul.149(8):4359-4366. Pubmedid: 36098856.
• Barker VR, Varkhedi M, Patel DN, Hsiang M, Chobrutskiy A, Chobrutskiy BI, Blanck G. TCR CDR3-antigen chemical complementarity associated with poor ovarian cancer outcomes: A vestigial immune response to early cancer antigens?. Am J Reprod Immunol. 2023 Jan.89(1):e13639. Pubmedid: 36317868.
• Zaman S, Chobrutskiy BI, Quach JU, Blanck G. Specific Intratumor Bacteria Genera and TRG Recombinations Associated with Greater Survival Probability in Alimentary Tract Cancers. J Gastrointest Cancer. 2023 Dec.54(4):1300-1307. Pubmedid: 37103748.
• Song JJ, Chobrutskiy A, Chobrutskiy BI, Cios KJ, Huda TI, Eakins RA, Diaz MJ, Blanck G. Chemical Complementarity of Tumor Resident, Adaptive Immune Receptor CDR3s and Previously Defined Hepatitis C Virus Epitopes Correlates with Improved Outcomes in Hepatocellular Carcinoma. Viral Immunol. 2023 Dec.36(10):669-677. Pubmedid: 38052065.
• Kinskey JC, Huda TI, Gozlan EC, Quach JU, Arturo JF, Chobrutskiy A, Chobrutskiy BI, Blanck G. The presence of intratumoral Porphyromonas gingivalis correlates with a previously defined pancreatic adenocarcinoma, immune cell expression phenotype and with tumor resident, adaptive immune receptor features. Carcinogenesis. 2023 Aug.44(5):411-417. Pubmedid: 37195907.
• Wolmarans HJ, Barker VR, Chobrutskiy A, Chobrutskiy BI, Huda TI, Blanck G. Exploiting big data survival information to unify risk-stratification related, adaptive immune receptor parameters for multiple myeloma. Genes Immun. 2023 Aug.24(4):194-199. Pubmedid: 37443300.
• Song JJ, Chobrutskiy A, Chobrutskiy BI, Cios KJ, Huda TI, Eakins RA, Diaz MJ, Blanck G. TRB CDR3 chemical complementarity with HBV epitopes correlates with increased hepatocellular carcinoma, disease-free survival. J Med Virol. 2023 Aug.95(8):e29043. Pubmedid: 37621059.
• Agnila DRL, Huda TI, Eakins RA, Patel DN, Hsiang M, Chobrutskiy A, Chobrutskiy BI, Blanck G. Chemical features of melanoma tumor resident TRG CDR3s associated with better survival probabilities. Melanoma Res. 2023 Aug.33(4):275-282. Pubmedid: 37222076.
• Arias MA, Cios KJ, Kacsoh DB, Montgomery BE, Song JJ, Patel AR, Chobrutskiy A, Chobrutskiy BI, Blanck G. Electrostatic Complementarities of Glioblastoma-Resident T-Cell Receptors and Cancer Testis Antigens Linked to Poor Outcomes and High Levels of Sphingosine Kinase-2 Expression. Biology (Basel). 2023 Apr.12(4). Pubmedid: 37106775. Pmcid: PMC10135705.
• Diaz MJ, Kacsoh DB, Patel DN, Yeagley M, Hsiang M, Blanck G. Tumor resident, TRA anti-viral CDR3 chemical sequence motifs are associated with a better breast cancer outcome. Genes Immun. 2023 Apr.24(2):92-98. Pubmedid: 36805542.
• Angelakakis G, Serraneau KS, Barker VR, Callahan BM, Tong WL, Zaman S, Huda TI, Blanck G. TCR gene segment usage and HLA alleles that are associated with cancer survival rates also represent racial disparities. Int J Immunogenet. 2023 Apr.50(2):41-47. Pubmedid: 36585798.
• Kacsoh DB, Patel DN, Hsiang M, Gozlan EC, Chobrutskiy A, Chobrutskiy BI, Blanck G. Tumor Resident, B-Cell Receptor Chemical Characteristics Associated with Better Overall Survival for Neuroblastoma. J Mol Neurosci. 2022 Sep.72(9):2011-2019. Pubmedid: 35896862.
• Eakins RA, Chobrutskiy A, Teer JK, Patel DN, Hsiang M, Huda TI, Zaman S, Sexton WJ, Coppola D, Falasiri S, Blanck G, Chobrutskiy BI. Chemical complementarity between tumor resident, T-cell receptor CDR3s and MAGEA3/6 correlates with increased melanoma survival: Potential relevance to MAGE vaccine auto-reactivity. Mol Immunol. 2022 Oct.150:58-66. Pubmedid: 35987136.
• Gozlan EC, Chobrutskiy BI, Blanck G. Exploiting adaptive immune receptor recombination read recoveries from exome files to identify subsets of ALL and to establish TCR features that correlate with better outcomes. Int J Lab Hematol. 2022 Oct.44(5):883-891. Pubmedid: 35527672.
• Ferrall-Fairbanks MC, Chakiryan N, Chobrutskiy BI, Kim Y, Teer JK, Berglund A, Mulé JJ, Fournier M, Siegel EM, Dhillon J, Falasiri SSA, Arturo JF, Katende EN, Blanck G, Manley BJ, Altrock PM. Quantification of T- and B-cell Immune Receptor Distribution Diversity Characterizes Immune Cell Infiltration and Lymphocyte Heterogeneity in Clear Cell Renal Cell Carcinoma. Cancer Res. 2022 Mar.82(5):929-942. Pubmedid: 35031572. Pmcid: PMC8898280.
• Cios KJ, Huda TI, Eakins RA, Mihyu MM, Blanck G. Specific TCR V-J gene segment recombinations leading to the identification pan-V-J CDR3s associated with survival distinctions: diffuse large B-cell lymphoma. Leuk Lymphoma. 2022 Jun.63(6):1314-1322. Pubmedid: 35019822.
• Husain K, Villalobos-Ayala K, Laverde V, Vazquez OA, Miller B, Kazim S, Blanck G, Hibbs ML, Krystal G, Elhussin I, Mori J, Yates C, Ghansah T. Apigenin Targets MicroRNA-155, Enhances SHIP-1 Expression, and Augments Anti-Tumor Responses in Pancreatic Cancer. Cancers (Basel). 2022 Jul.14(15). Pubmedid: 35892872. Pmcid: PMC9331563.
• Huda TI, Diaz MJ, Gozlan EC, Chobrutskiy A, Chobrutskiy BI, Blanck G. Immunogenomics Parameters for Patient Stratification in Alzheimer's Disease. J Alzheimers Dis. 2022 Jul.88(2):619-629. Pubmedid: 35662120.
• Blanck G. Time to consider sequencing anti-inflammatory treatments with chemotherapy and immuno-stimulation?. Front Immunol. 2022 Dec.13:1082142. Pubmedid: 36618422. Pmcid: PMC9817152.
• Varkhedi M, Barker VR, Eakins RA, Blanck G. CNV assessments associated with outcome distinctions for adult and pediatric cancers: Loss of BRCA1 in neuroblastoma associates with a lower survival probability. Gene. 2022 Aug.836:146673. Pubmedid: 35714795.
• Mcbreairty BE, Chobrutskiy BI, Chobrutskiy A, Gozlan EC, Diaz MJ, Blanck G. Immune receptor CDR3 chemical features that preserve sequence information are highly efficient in reflecting survival distinctions: A pan-cancer analysis. Biomed Rep. 2022 Aug.17(2):68. Pubmedid: 35815190. Pmcid: PMC9260149.
• Patel DN, Yeagley M, Arturo JF, Falasiri S, Chobrutskiy BI, Gozlan EC, Blanck G. A comparison of immune receptor recombination databases sourced from tumour exome or RNAseq files: Verifications of immunological distinctions between primary and metastatic melanoma. Int J Immunogenet. 2021 Oct.48(5):409-418. Pubmedid: 34298587.
• Gozlan EC, Chobrutskiy BI, Zaman S, Yeagley M, Blanck G. Systemic Adaptive Immune Parameters Associated with Neuroblastoma Outcomes: the Significance of Gamma-Delta T Cells. J Mol Neurosci. 2021 Nov.71(11):2393-2404. Pubmedid: 33666857.
• Hsiang M, Chobrutskiy BI, Diaz M, Huda TI, Creadore S, Zaman S, Cios KJ, Gozlan EC, Blanck G. Chemical complementarity between immune receptors and cancer mutants, independent of antigen presentation protein binding, is associated with increased survival rates. Transl Oncol. 2021 Jun.14(6):101069. Pubmedid: 33780706. Pmcid: PMC8039726.
• Huda TI, Mihyu M, Gozlan EC, Arndt MF, Diaz MJ, Zaman S, Chobrutskiy BI, Blanck G. Specific HLA alleles, paired with TCR V- and J-gene segment usage, link to distinct multiple myeloma survival rates. Leuk Lymphoma. 2021 Jul.62(7):1711-1720. Pubmedid: 33622167.
• Chobrutskiy BI, Chobrutskiy A, Zaman S, Yeagley M, Huda TI, Blanck G. High-throughput, sliding-window algorithm for assessing chemical complementarity between immune receptor CDR3 domains and cancer mutant peptides: TRG-PIK3CA interactions and breast cancer. Mol Immunol. 2021 Jul.135:247-253. Pubmedid: 33933816.
• Chobrutskiy A, Chobrutskiy BI, Zaman S, Hsiang M, Blanck G. Chemical features of blood-borne TRG CDR3s associated with an increased overall survival in breast cancer. Breast Cancer Res Treat. 2021 Feb.185(3):591-600. Pubmedid: 33180235.
• Yeagley M, Chobrutskiy BI, Gozlan EC, Medikonda N, Patel DN, Falasiri S, Callahan BM, Huda T, Blanck G. Electrostatic Complementarity of T-Cell Receptor-Alpha CDR3 Domains and Mutant Amino Acids Is Associated with Better Survival Rates for Sarcomas. Pediatr Hematol Oncol. 2021 Apr.38(3):251-264. Pubmedid: 33616477.
• Zaman S, Chobrutskiy BI, Patel JS, Diviney A, Tu YN, Tong WL, Gill T, Blanck G. Antiviral T Cell Receptor Complementarity Determining Region-3 Sequences Are Associated with a Worse Cancer Outcome: A Pancancer Analysis. Viral Immunol. 2020 Jun.33(5):404-412. Pubmedid: 32315578.
• Christley S, Aguiar A, Blanck G, Breden F, Bukhari SAC, Busse CE, Jaglale J, Harikrishnan SL, Laserson U, Peters B, Rocha A, Schramm CA, Taylor S, Vander Heiden JA, Zimonja B, Watson CT, Corrie B, Cowell LG. The ADC API: A Web API for the Programmatic Query of the AIRR Data Commons. Front Big Data. 2020 Jun.3:22. Pubmedid: 33693395. Pmcid: PMC7931935.
• Arturo JF, Chobrutskiy BI, Yeagley M, Patel DN, Falasiri S, Patel JS, Blanck G. Electrostatic complementarity of B-cell receptor CDR3s and TP53-mutant amino acids in breast cancer is associated with increased disease-free survival rates. Cell Mol Immunol. 2020 Jul.17(7):776-778. Pubmedid: 31729463. Pmcid: PMC7331692.
• Chobrutskiy BI, Yeagley M, Tipping P, Zaman S, Diviney A, Patel DN, Falasiri S, Uversky VN, Blanck G. Chemical complementarity between immune receptor CDR3s and IDH1 mutants correlates with increased survival for lower grade glioma. Oncogene. 2020 Feb.39(8):1773-1783. Pubmedid: 31740784.
• Arndt MF, Koohestani DM, Chobrutskiy BI, Mihyu MM, Diaz M, Gozlan EC, Yeagley M, Zaman S, Roca AM, Blanck G. TRBV and TRBJ usage, when paired with specific HLA alleles, associates with distinct head and neck cancer survival rates. Hum Immunol. 2020 Dec.81(12):692-696. Pubmedid: 32950267.
• Diaz MJ, Chobrutskiy BI, Zaman S, Blanck G. Immunogenomics of colorectal adenocarcinoma: Survival distinctions represented by immune receptor, CDR3 chemical features and high expression of BTN gene family members. Cancer Treat Res Commun. 2020 Aug.24:100196. Pubmedid: 32769037.
• Tu YN, Tong WL, Callahan BM, Chobrutskiy BI, Blanck G. B-cell Receptor Recombinations in Lung Adenocarcinoma Exome Files Correlate With a Higher Overall Survival Rate. Anticancer Res. 2020 Apr.40(4):2043-2051. Pubmedid: 32234895.
• Chobrutskiy BI, Yeagley M, Diviney A, Zaman S, Gozlan EC, Tipping P, Koohestani DM, Roca AM, Blanck G. A scoring system for the electrostatic complementarities of T-cell receptors and cancer-mutant amino acids: multi-cancer analyses of associated survival rates. Immunology. 2020 Apr.159(4):373-383. Pubmedid: 31821535. Pmcid: PMC7077996.
• Zaman S, Chobrutskiy BI, Patel JS, Callahan BM, Mihyu MM, Diviney A, Blanck G. Potential MMP2-mediated availability of HLA binding, mutant ECM peptides reflects better melanoma survival rates and greater T-cell infiltrates. Lab Invest. 2019 Sep.99(9):1287-1295. Pubmedid: 31019293.
• Chobrutskiy BI, Zaman S, Diviney A, Mihyu MM, Blanck G. T-cell receptor-α CDR3 domain chemical features correlate with survival rates in bladder cancer. J Cancer Res Clin Oncol. 2019 Mar.145(3):615-623. Pubmedid: 30539280.
• Diviney A, Chobrutskiy BI, Zaman S, Blanck G. An age-based, RNA expression paradigm for survival biomarker identification for pediatric neuroblastoma and acute lymphoblastic leukemia. Cancer Cell Int. 2019 Mar.19:73. Pubmedid: 30962767. Pmcid: PMC6438000.
• Patel JS, Callahan BM, Chobrutskiy BI, Blanck G. Matrix-Metalloprotease Resistant Mucin-16 (MUC16) Peptide Mutants Represent a Worse Lung Adenocarcinoma Outcome. Proteom Clin Appl. 2019 Jul.13(4):e1800155. Pubmedid: 30790454.
• Zaman S, Chobrutskiy BI, Patel JS, Callahan BM, Tong WL, Mihyu MM, Blanck G. MMP7 sensitivity of mutant ECM proteins: An indicator of melanoma survival rates and T-cell infiltration. Clin Biochem. 2019 Jan.63:85-91. Pubmedid: 30414845.
• Tong WL, Callahan BM, Tu YN, Zaman S, Chobrutskiy BI, Blanck G. Immune receptor recombinations from breast cancer exome files, independently and in combination with specific HLA alleles, correlate with better survival rates. Breast Cancer Res Treat. 2019 Jan.173(1):167-177. Pubmedid: 30229447.
• Clark KR, Tong WL, Callahan BM, Yavorski JM, Tu YN, Blanck G. TRB-J1 usage, in combination with the HLA-A*01:01 allele, represents an apparent survival advantage for uterine corpus endometrial carcinoma: Comparisons with microscopic assessments of lymphocyte infiltrates. Int J Immunogenet. 2019 Feb.46(1):31-37. Pubmedid: 30474304.
• Zaman S, Chobrutskiy BI, Sikaria D, Blanck G. MAPT (Tau) expression is a biomarker for an increased rate of survival for low‑grade glioma. Oncol Rep. 2019 Feb.41(2):1359-1366. Pubmedid: 30535461.
• Pakasticali N, Gill T, Chobrutskiy BI, Tong WL, Ramsamooj M, Blanck G. TRAV gene segments further away from the TRAJ gene segment cluster appear more commonly in human tumor and blood samples. Mol Immunol. 2019 Dec.116:174-179. Pubmedid: 31704500.
• Roca AM, Chobrutskiy BI, Callahan BM, Blanck G. T-cell receptor V and J usage paired with specific HLA alleles associates with distinct cervical cancer survival rates. Hum Immunol. 2019 Apr.80(4):237-242. Pubmedid: 30684568.
• Zaman S, Chobrutskiy BI, Blanck G. MAPT (Tau) expression is a biomarker for an increased rate of survival in pediatric neuroblastoma. Cell Cycle. 2018 Nov.17(21-22):2474-2483. Pubmedid: 30394813. Pmcid: PMC6342068.
• Sikaria D, Tu YN, Fisler DA, Mauro JA, Blanck G. Identification of specific feed-forward apoptosis mechanisms and associated higher survival rates for low grade glioma and lung squamous cell carcinoma. J Cancer Res Clin Oncol. 2018 Mar.144(3):459-468. Pubmedid: 29305708.
• Kinskey JC, Tu YN, Tong WL, Yavorski JM, Blanck G. Recovery of Immunoglobulin VJ Recombinations from Pancreatic Cancer Exome Files Strongly Correlates with Reduced Survival. Cancer Microenviron. 2018 Jun.11(1):51-59. Pubmedid: 29404962. Pmcid: PMC6008263.
• Tu YN, Tong WL, Yavorski JM, Blanck G. Immunogenomics: A Negative Prostate Cancer Outcome Associated with TcR-γ/δ Recombinations. Cancer Microenviron. 2018 Jun.11(1):41-49. Pubmedid: 29357011. Pmcid: PMC6008264.
• Mai AT, Tong WL, Tu YN, Blanck G. TcR-α recombinations in renal cell carcinoma exome files correlate with an intermediate level of T-cell exhaustion biomarkers. Int Immunol. 2018 Feb.30(1):35-40. Pubmedid: 29361059. Pmcid: PMC7958811.
• Chobrutskiy BI, Zaman S, Tong WL, Diviney A, Blanck G. Recovery of T-cell receptor V(D)J recombination reads from lower grade glioma exome files correlates with reduced survival and advanced cancer grade. J Neurooncol. 2018 Dec.140(3):697-704. Pubmedid: 30382482.
• Falasiri S, Rahman T, Tu YN, Fawcett TJ, Blanck G. Germline cytoskeletal and extra-cellular matrix-related single nucleotide variations associated with distinct cancer survival rates. Gene. 2018 Aug.669:91-98. Pubmedid: 29778426.
• Fisler DA, Sikaria D, Yavorski JM, Tu YN, Blanck G. Elucidating feed-forward apoptosis signatures in breast cancer datasets: Higher FOS expression associated with a better outcome. Oncol Lett. 2018 Aug.16(2):2757-2763. Pubmedid: 30013671. Pmcid: PMC6036554.
• Zaman S, Chobrutskiy BI, Patel JS, Callahan BM, Tong WL, Blanck G. Mutant cytoskeletal and ECM peptides sensitive to the ST14 protease are associated with a worse outcome for glioblastoma multiforme. Biochem Bioph Res Co. 2018 09.503(4):2218-2225. Pubmedid: 29953855.
• Callahan BM, Yavorski JM, Tu YN, Tong WL, Kinskey JC, Clark KR, Fawcett TJ, Blanck G. T-cell receptor-β V and J usage, in combination with particular HLA class I and class II alleles, correlates with cancer survival patterns. Cancer Immunol Immun. 2018 06.67(6):885-892. Pubmedid: 29508024.
• Callahan BM, Tong WL, Blanck G. T cell receptor-β J usage, in combination with particular HLA class II alleles, correlates with better cancer survival rates. Immunol Res. 2018 04.66(2):219-223. Pubmedid: 29594966.
• Callahan BM, Patel JS, Fawcett TJ, Blanck G. Cytoskeleton and ECM tumor mutant peptides: Increased protease sensitivities and potential consequences for the HLA class I mutant epitope reservoir. Int J Cancer. 2018 03.142(5):988-998. Pubmedid: 29047110.
• Uversky VN, Tu YN, Nwogu O, Butler SN, Ramsamooj M, Blanck G. High-level intrinsic disorder explains the universality of CLIP binding to diverse MHC class II variants. Cell Mol Immunol. 2018 01.15(1):76-78. Pubmedid: 28757614. Pmcid: PMC5827175.
• Mauro JA, Yavorski JM, Blanck G. Stratifying melanoma and breast cancer TCGA datasets on the basis of the CNV of transcription factor binding sites common to proliferation- and apoptosis-effector genes. Gene. 2017 May.614:37-48. Pubmedid: 28257835.
• Tong WL, Tu YN, Samy MD, Sexton WJ, Blanck G. Identification of immunoglobulin V(D)J recombinations in solid tumor specimen exome files: Evidence for high level B-cell infiltrates in breast cancer. Hum Vaccin Immunother. 2017 Mar.13(3):501-506. Pubmedid: 28085544. Pmcid: PMC5360147.
• Samy MD, Tong WL, Yavorski JM, Sexton WJ, Blanck G. T cell receptor gene recombinations in human tumor specimen exome files: detection of T cell receptor-β VDJ recombinations associates with a favorable oncologic outcome for bladder cancer. Cancer Immunol Immun. 2017 Mar.66(3):403-410. Pubmedid: 27995306.
• Yavorski JM, Stoll RJ, Samy MD, Mauro JA, Blanck G. Identification of Sets of Cytoskeletal Related and Adhesion-related Coding Region Mutations in the TCGA Melanoma Dataset that Correlate with a Negative Outcome. Curr Genomics. 2017 Jun.18(3):287-297. Pubmedid: 28659724. Pmcid: PMC5476947.
• Tu YN, Tong WL, Samy MD, Yavorski JM, Kim M, Blanck G. Assessing microenvironment immunogenicity using tumor specimen exomes: Co-detection of TcR-α/β V(D)J recombinations correlates with PD-1 expression. Int J Cancer. 2017 Jun.140(11):2568-2576. Pubmedid: 28256716.
• Stoll RJ, Thompson GR, Samy MD, Blanck G. De novo, systemic, deleterious amino acid substitutions are common in large cytoskeleton-related protein coding regions. Biomed Rep. 2017 Feb.6(2):211-216. Pubmedid: 28357075. Pmcid: PMC5351269.
• Clark NM, Garcia Galindo CA, Patel VK, Parry ML, Stoll RJ, Yavorski JM, Pinkason EP, Johnson EM, Walker CM, Johnson J, Sexton WJ, Coppola D, Blanck G. The human, F-actin-based cytoskeleton as a mutagen sensor. Cancer Cell Int. 2017 Dec.17:121. Pubmedid: 29255378. Pmcid: PMC5727871.
• Yavorski JM, Blanck G. MHC class II associated stomach cancer mutations correlate with lack of subsequent tumor development. Mol Clin Oncol. 2017 Dec.7(6):1119-1121. Pubmedid: 29285385. Pmcid: PMC5740846.
• Tu YN, Tong WL, Fawcett TJ, Blanck G. Lung tumor exome files with T-cell receptor recombinations: a mouse model of T-cell infiltrates reflecting mutation burdens. Lab Invest. 2017 Dec.97(12):1516-1520. Pubmedid: 28805806.
• Segarra DT, Yavorski JM, Blanck G. Protected cytoskeletal-related proteins: Towards a resolution of contradictions regarding the role of the cytoskeleton in cancer. Biomed Rep. 2017 Aug.7(2):163-168. Pubmedid: 28804630. Pmcid: PMC5526129.
• Sait S, Fawcett T, Blanck G. Overlap of the cancer genome atlas and the immune epitope database. Oncol Lett. 2016 Oct.12(4):2982-2984. Pubmedid: 27703532. Pmcid: PMC5038905.
• Samy MD, Yavorski JM, Mauro JA, Blanck G. Impact of SNPs on CpG Islands in the MYC and HRAS oncogenes and in a wide variety of tumor suppressor genes: A multi-cancer approach. Cell Cycle. 2016 Jun.15(12):1572-1578. Pubmedid: 27074591. Pmcid: PMC4934054.
• Butler SN, Blanck G. Immunoscoring by correlating MHC class II and TCR expression: high level immune functions represented by the KIRP dataset of TCGA. Cell Tissue Res. 2016 Feb.363(2):491-496. Pubmedid: 26293619.
• Gill TR, Samy MD, Butler SN, Mauro JA, Sexton WJ, Blanck G. Detection of Productively Rearranged TcR-α V-J Sequences in TCGA Exome Files: Implications for Tumor Immunoscoring and Recovery of Antitumor T-cells. Cancer Inform. 2016 Feb.15:23-28. Pubmedid: 26966347. Pmcid: PMC4768948.
• Parry ML, Blanck G. Flat cells come full sphere: Are mutant cytoskeletal-related proteins oncoprotein-monsters or useful immunogens?. Hum Vaccin Immunother. 2016 Dec.12(1):120-123. Pubmedid: 26225584. Pmcid: PMC4962751.
• Yavorski JM, Blanck G. Smoking correlates with increased cytoskeletal protein-related coding region mutations in the lung and head and neck datasets of the cancer genome atlas. Physiol Rep. 2016 Dec.4(24). Pubmedid: 28039401. Pmcid: PMC5210378.
• Yavorski JM, Blanck G. TCGA: Increased oncoprotein coding region mutations correlate with a greater expression of apoptosis-effector genes and a positive outcome for stomach adenocarcinoma. Cell Cycle. 2016 Aug.15(16):2157-2163. Pubmedid: 27355872. Pmcid: PMC4993568.
• Blazekovic F, Odukoya D, Butler SN, Mauro JA, Ramsamooj M, Puleo E, Szekeres K, Dana D, Kumar S, Ragupathi G, Blanck G. HLA-DR peptide occupancy can be regulated with a wide variety of small molecules. Hum Vaccin Immunother. 2016 03.12(3):593-598. Pubmedid: 26453454. Pmcid: PMC4964726.
• Blanck G. The future of cancer research: prevention, screening, vaccines, and tumor-specific drug combos. Hum Vaccin Immunother. 2015 Mar.10(3):700-702. Pubmedid: 24346686. Pmcid: PMC4130267.
• Frangione ML, Lockhart JH, Morton DT, Pava LM, Blanck G. Anticipating designer drug-resistant cancer cells. Drug Discov Today. 2015 Jul.20(7):790-793. Pubmedid: 25697478.
• Mauro JA, Butler S, Ramsamooj M, Blanck G. Copy number loss or silencing of apoptosis-effector genes in cancer. Gene. 2015 Jan.554(1):50-57. Pubmedid: 25307873.
• Parry ML, Ramsamooj M, Blanck G. Big genes are big mutagen targets: a connection to cancerous, spherical cells?. Cancer Lett. 2015 Jan.356(2 Pt B):479-482. Pubmedid: 25451318.
• Lloyd MC, Szekeres K, Brown JS, Blanck G. Class II transactivator expression in melanoma cells facilitates T-cell engulfment. Anticancer Res. 2015 Jan.35(1):25-29. Pubmedid: 25550531.
• Ford SA, Blanck G. Signal persistence and amplification in cancer development and possible, related opportunities for novel therapies. Biochim Biophys Acta. 2015 Jan.1855(1):18-23. Pubmedid: 25450826.
• Garcia M, Mauro JA, Ramsamooj M, Blanck G. Tumor suppressor genes are larger than apoptosis-effector genes and have more regions of active chromatin: Connection to a stochastic paradigm for sequential gene expression programs. Cell Cycle. 2015 Aug.14(15):2494-2500. Pubmedid: 25945879. Pmcid: PMC4615035.
• Blanck G. Letter to the Editor: Giant proteins and cancer chemotherapy cardiotoxicity. Am J Physiol Heart Circ Physiol. 2015 Aug.309(4):H718. Pubmedid: 26276978.
• Blanck G. The Rise of the Biomedical Sciences Master's Program at U.S. Medical Colleges. Teach Learn Med. 2014 Oct.26(4):409-411. Pubmedid: 25318038.
• Mauro JA, Blanck G. Functionally distinct gene classes as bigger or smaller transcription factor traps: a possible stochastic component to sequential gene expression programs in cancer. Gene. 2014 Feb.536(2):398-406. Pubmedid: 24291030.
• Szekeres K, Koul R, Mauro J, Lloyd M, Johnson J, Blanck G. An Oct-1-based, feed-forward mechanism of apoptosis inhibited by co-culture with Raji B-cells: towards a model of the cancer cell/B-cell microenvironment. Exp Mol Pathol. 2014 Dec.97(3):585-589. Pubmedid: 25236570. Pmcid: PMC4742287.
• Pillai S, Szekeres K, Lawrence NJ, Chellappan SP, Blanck G. Regulation of interlocking gene regulatory network subcircuits by a small molecule inhibitor of retinoblastoma protein (RB) phosphorylation: cancer cell expression of HLA-DR. Gene. 2013 Jan.512(2):403-407. Pubmedid: 23041127.
• Cronin K, Escobar H, Szekeres K, Reyes-Vargas E, Rockwood AL, Lloyd MC, Delgado JC, Blanck G. Regulation of HLA-DR peptide occupancy by histone deacetylase inhibitors. Hum Vaccin Immunother. 2013 Apr.9(4):784-789. Pubmedid: 23328677. Pmcid: PMC3903896.
• Pava LM, Morton DT, Chen R, Blanck G. Unifying the Genomics-based Classes of Cancer Fusion Gene Partners: Large Cancer Fusion Genes Are Evolutionarily Conserved. Cancer Genomics Proteomics. 2012 Nov.9(6):389-395. Pubmedid: 23162078.
• Long K, Abuelenen T, Pava L, Bastille M, Blanck G. Size matters: sequential mutations in tumorigenesis may reflect the stochastic effect of mutagen target sizes. Genes Cancer. 2011 Oct.2(10):927-931. Pubmedid: 22701759. Pmcid: PMC3374629.
• Coppola D, Parikh V, Boulware D, Blanck G. Substantially reduced expression of PIAS1 is associated with colon cancer development. J Cancer Res Clin Oncol. 2009 Sep.135(9):1287-1291. Pubmedid: 19288270.
• Niesen MI, Osborne AR, Lagor WR, Zhang H, Kazemfar K, Ness GC, Blanck G. Technological advances in the study of HLA-DRA promoter regulation: extending the functions of CIITA, Oct-1, Rb, and RFX. Acta Biochim Biophys Sin (Shanghai). 2009 Mar.41(3):198-205. Pubmedid: 19280058.
• Niesen MI, Blanck G. Rescue of major histocompatibility-DR surface expression in retinoblastoma-defective, non-small cell lung carcinoma cells by the MS-275 histone deacetylase inhibitor. Biol Pharm Bull. 2009 Mar.32(3):480-482. Pubmedid: 19252299.
• Narsing S, Jelsovsky Z, Mbah A, Blanck G. Genes that contribute to cancer fusion genes are large and evolutionarily conserved. Cancer Genet Cytogenet. 2009 Jun.191(2):78-84. Pubmedid: 19446742.
• Kazemfar K, Chen R, Nicholson K, Coppola D, Zhou JM, Chen X, Wei S, Blanck G. Combined IL-8 and TGF-beta blockade efficiently prevents neutrophil infiltrates into an A549-cell tumor. Immunol Lett. 2009 Jan.122(1):25-29. Pubmedid: 19056425.
• Xu L, Niesen MI, Blanck G. Linkage of a tumor immune function and cell cycle de-regulation via a gene regulatory network subcircuit. Mol Immunol. 2009 Feb.46(4):569-575. Pubmedid: 18952290.
• Osborne AR, Zhang H, Blanck G. Oct-1 DNA binding activity unresponsive to retinoblastoma protein expression prevents MHC class II induction in a non-small cell lung carcinoma cell line. Mol Immunol. 2006 Feb.43(6):710-716. Pubmedid: 16360016.
• Niesen MI, Osborne AR, Yang H, Rastogi S, Chellappan S, Cheng JQ, Boss JM, Blanck G. Activation of a methylated promoter mediated by a sequence-specific DNA-binding protein, RFX. J Biol Chem. 2005 Nov.280(47):38914-38922. Pubmedid: 16166088.
• Osborne AR, Zhang H, Fejer G, Palubin KM, Niesen MI, Blanck G. Oct-1 maintains an intermediate, stable state of HLA-DRA promoter repression in Rb-defective cells: an Oct-1-containing repressosome that prevents NF-Y binding to the HLA-DRA promoter. J Biol Chem. 2004 Jul.279(28):28911-28919. Pubmedid: 15105429.
• Blanck G. Mutations and regulatory anomalies effecting tumor cell immune functions. Cancer Immunol Immun. 2004 Jan.53(1):1-16. Pubmedid: 13680191.
• Eason D, LeBron C, Coppola D, Moscinski L, Livingston S, Sutton E, Blanck G. Development of CD30+ lymphoproliferative disease in mice lacking interferon regulatory factor-1. Oncogene. 2003 Sep.22(40):6166-6176. Pubmedid: 13679855.
• Xi H, Blanck G. The IRF-2 DNA binding domain facilitates the activation of the class II transactivator (CIITA) type IV promoter by IRF-1. Mol Immunol. 2003 Jan.39(11):677-684. Pubmedid: 12493643.
• Blanck G. Components of the IFN-gamma signaling pathway in tumorigenesis. Arch Immunol Ther Exp (Warsz). 2002.50(3):151-158. Pubmedid: 12098930.
• Eason D, Coppola D, Livingstone S, Blanck G, Shepherd A. Loss of MHC class II inducibility in hyperplastic tissue in Rb-defective mice. Cancer Lett. 2001 Oct.171(2):209-214. Pubmedid: 11520605.
• Osborne A, Zhang H, Yang W, Seto E, Blanck G. Histone deacetylase activity represses gamma interferon-inducible HLA-DR gene expression following the establishment of a DNase I-hypersensitive chromatin conformation. Mol Cell Biol. 2001 Oct.21(19):6495-6506. Pubmedid: 11533238. Pmcid: PMC99796.
• Goodwin B, Xi H, Tejiram R, Eason D, Ghosh D, Wright K, Nagarajan U, Boss J, Blanck G. Varying functions of specific major histocompatibility class II transactivator promoter III and IV elements in melanoma cell lines. Cell Growth Differ. 2001 Jun.12(6):327-335. Pubmedid: 11432807.
• Xi H, Goodwin B, Shepherd A, Blanck G. Impaired class II transactivator expression in mice lacking interferon regulatory factor-2. Oncogene. 2001.20(31):4219-4227. Pubmedid: 11464288.
• Eason D, Blanck G. High level class II trans-activator induction does not occur with transient activation of the IFN-gamma signaling pathway. J Immunol. 2001.166(2):1041-1048. Pubmedid: 11145683.
• Zhang H, Wei S, Sun J, Coppola D, Zhong B, Wu G, Goodwin B, Sebti S, Djeu JY, Blanck G. Retinoblastoma protein activation of interleukin 8 expression inhibits tumor cell survival in nude mice. Cell Growth Differ. 2000 Dec.11(12):635-639. Pubmedid: 11149598.
• Xi H, Blanck G. Interferon regulatory factor-2 point mutations in human pancreatic tumors. Int J Cancer. 2000.87(6):803-808. Pubmedid: 10956389.
• Xi H, Eason D, Ghosh D, Dovhey S, Wright K, Blanck G. Co-occupancy of the interferon regulatory element of the class II transactivator (CIITA) type IV promoter by interferon regulatory factors 1 and 2. Oncogene. 1999 Oct.18(43):5889-5903. Pubmedid: 10557076.
• Eason D, Shepherd A, Blanck G. Interferon regulatory factor 1 tryptophan 11 to arginine point mutation abolishes DNA binding. Biochim Biophys Acta. 1999 Jul.1446(1-2):140-144. Pubmedid: 10395927.
• Zhang H, Shephard AT, Eason DD, Wei S, Diaz JI, Djeu JY, Wu GD, Blanck G. Retinoblastoma protein expression leads to reduced Oct-1 DNA binding activity and enhances interleukin-8 expression. Cell Growth Differ. 1999 Jul.10(7):457-465. Pubmedid: 10437913.
• Osborne A, Tschickardt M, Blanck G. Retinoblastoma protein expression facilitates chromatin remodeling at the HLA-DRA promoter. Nucleic Acids Res. 1997.25:5095-5102. Pubmedid: 9396821.
• Lu Y, Tschickardt M, Schmidt B, Blanck G. IFN-gamma inducibility of CIITA is specifically lacking in human tumor lines: relevance to retinoblastoma protein rescue of IFN-gamma inducibility of the HLA class II genes. Immunol Cell Biol. 1997.75:325-332. Pubmedid: 9315472.
• Lu Y, Boss J, Hu S, Xu H, Blanck G. Apoptosis-independent retinoblastoma protein rescue of HLA class II messenger RNA IFN-gamma inducibility in non-small cell lung carcinoma cells. J Immunol. 1996.156:2495-2502. Pubmedid: 8786310.
• Berry D, Lu Y, Schmidt B, Fallon P, O'Connell C, Hu S, Xu H, Blanck G. Retinoblastoma protein inhiibits IFN-(gamma) induced apoptosis. Oncogene. 1996.12:1809-1819. Pubmedid: 8622902.
• Schmidt B, Carter S, Berry D, Blanck G. Vitamin D3 reduces the apoptotic effect of IFN-(gamma) but does not facilitate HLA class II inducibilitys in RB-defective cells. Cancer Lett. 1996.110:169-176. Pubmedid: 9018097.
• Tschickardt M, Lu Y, Jacim M, Ussery G, Steimle B, Mach B, Blanck G. RB and a novel E2F-1 binding protein in MHC class II deficient B-cell lines and normal IFN-gamma induction of the class II transactivator CIITA in class II noninducible RB-defective tumor lines. Int J Cancer. 1995.62:461-465. Pubmedid: 7635572.
• Palubin K, Goodwin B, Niesen M, Le E, Osborne A, Blanck G. A direct mechanistic link between growth control and a tumor cell immune function: increased interleukin-8 secretion accounts for elimination of Oct-1 antisense transformants from scid mice. Anticancer Res. 26(3A):1733-1738. Pubmedid: 16827100.
• Fawcett TJ, Parry ML, Blanck G. A Novel Approach to Evaluating Cancer Driver Gene Mutation Densities: Cytoskeleton-related Gene Candidates. Cancer Genomics Proteomics. 12(6):283-290. Pubmedid: 26543077.